Results 41 to 50 of about 97,001 (288)

Fibrin D-dimer, markers of coagulation activation and the risk of major ischaemic heart disease in the Caerphilly Study [PDF]

, 2001
We have previously reported that plasma fibrin D-dimer (a marker of turnover of cross-linked Fibrin) showed a strong and independent association with incident ischaemic heart disease (IHD) in the Caerphilly Study cohort of 1,998 men a-ed 49-65.
Lowe, G.D.O., Rumley, A., Rumley, J., Sweetnam, P.M., Yarnell, J.W.G.   +4 more
core   +1 more source

Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy

Clinical and applied thrombosis/hemostasis, 2019
Clinical uncertainty exists regarding which assay should be designated as the standard monitoring coagulation test for intravenous unfractionated heparin (UFH).
K. McLaughlin, J. Rimsans, K. Sylvester, J. Fanikos, D. Dorfman, Patricia Senna, J. Connors, S. Goldhaber   +7 more
semanticscholar   +1 more source

Timing and volume of fluid administration for patients with bleeding [PDF]

, 2003
Original article can be found at: http://www3.interscience.wiley.com Copyright John Wiley & Sons. ‘This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2003, Issue 3.
Bunn, Frances, Kwan, I., Roberts, I.
core   +1 more source

Mixing Studies in Patients With Prolonged Activated Partial Thromboplastin Time or Prothrombin Time.

Anesthesia and Analgesia, 2019
BACKGROUND Patients presenting for surgery may have isolated or combined prolonged activated partial thromboplastin time (aPTT) and/or prothrombin time (PT).
H. Benzon, M. Park, R. McCarthy, M. Kendall, P. Lindholm   +4 more
semanticscholar   +1 more source

Hereditary factor XII deficiency in an adult patient: A case report

SAGE Open Medical Case Reports, 2022
Factor XII deficiency is a rare autosomal recessive health condition usually discovered incidentally during routine coagulation screening before surgery after investigating a prolongation of the activated partial thromboplastin time.
Rehab Y Al-Ansari, Fatimah Al-Yami, Ghayah Almulhim, Alexander Woodman   +3 more
doaj   +1 more source

Intraoperative blood transfusions in highly alloimmunized patients undergoing orthotopic liver transplantation. [PDF]

, 1989
Intraoperative blood requirements were analyzed in patients undergoing primary orthotopic liver transplantation and divided into two groups on the basis of panel reactive antibody of pretransplant serum measured by lymphocytotoxicity testing.
Duquesnoy, RJ, Esquivel, CD, Kang, YG, Marino, IR, Starzl, TE, Weber, T   +5 more
core   +1 more source

Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial) [PDF]

, 2012
Introduction: Several observational studies suggest that statins modulate the pathophysiology of sepsis and may prevent its progression. The aim of this study was to determine if the acute administration of atorvastatin reduces sepsis progression in ...
Barnett, A. H., Cooke, Matthew, Hawkey, P. M., Hong, Tan, Jones, Alan, Linhartova, Lucie, Melody, Teresa, Patel, Jaimin M., Perkins, Gavin D., Smith, F. Gao, Snaith, Catherine, Thickett, David R.   +11 more
core   +3 more sources

Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms

Clinical and applied thrombosis/hemostasis, 2017
The purpose of this study was to compare the performance of anti-factor Xa concentration versus activated partial thromboplastin time (aPTT) monitoring with multiple indication-specific heparin nomograms.
Emily M Whitman-Purves, James C. Coons, T. Miller, Jeannine V Dinella, A. Althouse, M. Schmidhofer, Roy E. Smith   +6 more
semanticscholar   +1 more source

Immuno Magnetic Thermosensitive Liposomes For Cancer Therapy [PDF]

, 2019
The present work describes the encapsulation of the drug doxorubicin (DOX) in immuno paramagnetic thermosensitive liposomes. DOX is the most common chemotherapeutic agent for the treatment of a variety of carcinomas.
Alawak, Mohamad
core   +1 more source

Guidelines on fibrinogen assays [PDF]

, 2003
No abstract ...
Becker, Blanco, Blomback, Cambas, Chantarangkul, Chantarangkul, Chitolie, Chitolie, Clauss, Cremer, Cushman, De Cristofaro, De Maat, De Metz, Eliasson, Gaffney, Gordon D. O. Lowe, Hantgan, Haverkate, Hoffmann, Humphries, Ian J. Mackie, Jacobsson, Kitchen, Kluft, Lawrie, Lowe, Lowe, Ludlam, Machin, Mackie, Marder, MDA, MDA, Natelson, NCCLS, Nieuwenhuizen, Oosting, Palareti, Rampling, Ratnoff, Rosenson, Rossi, Samuel J. Machin, Steven Kitchen, Swain, Sweetnam, Sweetnam, Thompson, Van Der Bom, Vermylen, Whicher, World Health Organisation Report   +52 more
core   +1 more source